Related Experiment Video

Updated: Apr 30, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes

Huiyun Pan1, Rong Liu, Shengjie Li

  • 1Gerontology Center, The First Affiliated Hospital, Zhejiang University, No. 79, Qingchun Road, Hangzhou, 310003, Zhejiang, China.

Cell Biochemistry and Biophysics
|April 30, 2014
PubMed

Insights

Icotinib demonstrates significant efficacy in treating advanced non-small cell lung cancer, particularly in patients with epidermal growth factor receptor (EGFR) mutations. This targeted therapy shows comparable outcomes to Gefitinib, with manageable side effects.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Icotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective against non-small cell lung cancer (NSCLC).
  • Its efficacy in advanced NSCLC is comparable to Gefitinib, but EGFR phenotypes influence treatment outcomes.
  • Understanding Icotinib's performance across different EGFR phenotypes is crucial for optimizing NSCLC treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of Icotinib in advanced NSCLC patients with varying EGFR phenotypes.
  • To compare treatment outcomes between EGFR wild-type and mutant NSCLC patients receiving Icotinib.
  • To analyze survival data and adverse events associated with Icotinib therapy.

Main Methods:

  • Retrospective analysis of clinical data from advanced NSCLC patients treated with Icotinib (August 2011 - May 2013).
  • Kaplan-Meier analysis for survival analysis (progression-free survival and overall survival).
  • Categorization of patients into EGFR wild-type (18) and mutant (51) groups.

Main Results:

  • Icotinib showed significantly higher objective response rates (54.9% vs 11.1%) and disease control rates (86.3% vs 50.0%) in EGFR mutant vs wild-type patients (P < 0.0013).
  • Median progression-free survival was substantially longer for EGFR mutant patients (9.7 months) compared to wild-type (2.6 months) (P < 0.001).
  • Common adverse reactions included rash, diarrhea, and itching, mostly Grade I-II and tolerable.

Conclusions:

  • Icotinib is highly effective and an optimal regimen for advanced NSCLC patients with EGFR mutations.
  • Treatment outcomes differ significantly based on EGFR mutational status.
  • Icotinib exhibits a favorable safety profile with manageable adverse events in NSCLC patients.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689